Pages that link to "Q41980925"

The following pages link to Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma (Q41980925):

Displayed 50 items.

• Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research (Q26744094) ‎ (← links)
• The promise of immunotherapy in head and neck squamous cell carcinoma (Q26744433) ‎ (← links)
• Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies (Q26744446) ‎ (← links)
• Current clinical immunotherapeutic approaches for head and neck cancer (Q26745411) ‎ (← links)
• Immunotherapy for head and neck cancer: latest developments and clinical potential (Q26745428) ‎ (← links)
• The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications (Q26747516) ‎ (← links)
• Advanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches (Q26767046) ‎ (← links)
• Antagonists of PD-1 and PD-L1 in Cancer Treatment (Q26796311) ‎ (← links)
• Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites (Q26798402) ‎ (← links)
• Oral cavity and oropharyngeal squamous cell carcinoma--an update (Q26799210) ‎ (← links)
• Advancements in the Management of HPV-Associated Head and Neck Squamous Cell Carcinoma (Q26799543) ‎ (← links)
• Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma (Q26827104) ‎ (← links)
• In-situ tumor vaccination: Bringing the fight to the tumor (Q26991976) ‎ (← links)
• What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer? (Q27026269) ‎ (← links)
• Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids (Q27329648) ‎ (← links)
• PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. (Q27853379) ‎ (← links)
• Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors (Q28072532) ‎ (← links)
• Update on immune checkpoint inhibitors in gynecological cancers (Q28076497) ‎ (← links)
• Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy (Q29617774) ‎ (← links)
• Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis (Q29994668) ‎ (← links)
• Management of Oropharyngeal Cancer in the HPV Era. (Q30248326) ‎ (← links)
• Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines (Q30251868) ‎ (← links)
• Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors (Q30276874) ‎ (← links)
• Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages. (Q30358706) ‎ (← links)
• Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy (Q30578330) ‎ (← links)
• Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment (Q33560501) ‎ (← links)
• Chromosomal Alterations and Gene Expression Changes Associated with the Progression of Leukoplakia to Advanced Gingivobuccal Cancer. (Q33599609) ‎ (← links)
• Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. (Q33608156) ‎ (← links)
• hrHPV E5 oncoprotein: immune evasion and related immunotherapies. (Q33730462) ‎ (← links)
• Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy (Q33736664) ‎ (← links)
• Prognostic significance of LINE-1 hypomethylation in oropharyngeal squamous cell carcinoma. (Q33742722) ‎ (← links)
• Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review. (Q33770030) ‎ (← links)
• Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis (Q33788235) ‎ (← links)
• Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx. (Q33816576) ‎ (← links)
• Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives (Q33884361) ‎ (← links)
• Biological Features of Human Papillomavirus-related Head and Neck Cancers Contributing to Improved Response. (Q33908290) ‎ (← links)
• PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. (Q34283708) ‎ (← links)
• Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences (Q34354547) ‎ (← links)
• The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014 (Q34402325) ‎ (← links)
• Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy (Q34522172) ‎ (← links)
• PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment (Q35044301) ‎ (← links)
• Immunoprevention of human papillomavirus-associated malignancies (Q35044376) ‎ (← links)
• Detection of human papillomavirus (HPV) in clinical samples: evolving methods and strategies for the accurate determination of HPV status of head and neck carcinomas (Q35052911) ‎ (← links)
• EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy (Q35067875) ‎ (← links)
• Identification of a human papillomavirus-associated oncogenic miRNA panel in human oropharyngeal squamous cell carcinoma validated by bioinformatics analysis of the Cancer Genome Atlas (Q35143770) ‎ (← links)
• A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). (Q35238022) ‎ (← links)
• Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma (Q35329190) ‎ (← links)
• Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma (Q35329825) ‎ (← links)
• Tailored immunotherapy for HPV positive head and neck squamous cell cancer (Q35623980) ‎ (← links)
• HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management (Q35762184) ‎ (← links)